Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Operating Cost Ratio?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Operating Cost Ratio is 
0.41 (1Y +2.85% )

ALXN Stock Price & Operating Cost Ratio

Operating Cost Ratio for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Operating Cost Ratio

chevron_right 2021 0.45 -0.9x
( -7.4% / year avg)
chevron_left 1995 3.6
vertical_align_top Peak 119.27 +309x
vertical_align_bottom Bottom 0.38
arrow_drop_up # Up Years 11 11 of 27
years up.
arrow_drop_down # Down Years 16
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -50.0x faster than it's operating cost ratio over the same period.
  • If ALXN shrinks it's stock at the same rate as it's operating cost ratio (-7.4%/year) , it's stock price will shrink +46.4% and hit $50.4 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 11 years (0%) it's operating cost ratio were also up.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Operating Cost Ratio Table

    Year Operating Cost Ratio YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.45 17.5% - -
    4/1/2020 0.38 -7.0% - -
    4/1/2019 0.41 -5.9% - -
    4/1/2018 0.44 -13.7% - -
    4/1/2017 0.51 -9.2% - -
    4/1/2016 0.56 0.1% - -
    4/1/2015 0.56 14.6% - -
    4/1/2014 0.49 -5.4% - -
    4/1/2013 0.52 0.9% - -
    4/1/2012 0.51 -8.8% - -
    4/1/2011 0.56 -6.3% - -
    4/1/2010 0.6 -5.6% - -
    4/1/2009 0.63 -29.8% - -
    4/1/2008 0.9 -86.1% - -
    4/1/2007 6.51 -87.2% - -
    4/1/2006 50.96 -57.3% - -
    4/1/2005 119.27 37.0% - -
    4/1/2004 87.03 -24.1% - -
    4/1/2003 114.63 254.1% - -
    4/1/2002 32.37 641.2% - -
    4/1/2001 4.37 73.9% - -
    4/1/2000 2.51 95.6% - -
    4/1/1999 1.28 -84.1% - -
    4/1/1998 8.08 198.0% - -
    4/1/1997 2.71 -16.6% - -
    4/1/1996 3.25 -9.7% - -
    4/1/1995 3.6 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Operating Cost Ratio = Operating Cost/Net Sales X 100


    For more detailed definitions, please see Investopedia.
    Year Operating Cost Ratio YoY % Change Stock Price YoY % Change (Stock Price) net revenue d n a total opex
    4/1/2021 0.45 17.5% 6367.20 300.40 3170.40
    4/1/2020 0.38 -7.0% 5862.40 344.90 2588.40
    4/1/2019 0.41 -5.9% 4735.60 384.60 2336.50
    4/1/2018 0.44 -13.7% 3912.50 492.60 2199.90
    4/1/2017 0.51 -9.2% 3440.11 411.68 2158.85
    4/1/2016 0.56 0.1% 2873.36 384.45 1990.27
    4/1/2015 0.56 14.6% 2502.66 91.41 1488.95
    4/1/2014 0.49 -5.4% 2076.17 36.85 1051.81
    4/1/2013 0.52 0.9% 1429.96 26.51 762.66
    4/1/2012 0.51 -8.8% 1041.15 22.03 552.76
    4/1/2011 0.56 -6.3% 711.85 17.13 415.63
    4/1/2010 0.60 -5.6% 495.63 15.40 310.26
    4/1/2009 0.63 -29.8% 353.55 11.01 233.64
    4/1/2008 0.90 -86.1% 215.56 7.25 186.27
    4/1/2007 6.51 -87.2% 43.11 4.26 161.96
    4/1/2006 50.96 -57.3% 6.67 3.30 121.81
    4/1/2005 119.27 37.0% 1.38 3.86 125.82
    4/1/2004 87.03 -24.1% 4.61 3.54 77.94
    4/1/2003 114.63 254.1% 0.69 3.71 81.86
    4/1/2002 32.37 641.2% 5.00 3.52 78.60
    4/1/2001 4.37 73.9% 10.12 5.54 47.53
    4/1/2000 2.51 95.6% 18.43 2.28 45.27
    4/1/1999 1.28 -84.1% 34.05 1.10 34.10
    4/1/1998 8.08 198.0% 7.35 0.70 16.60
    4/1/1997 2.71 -16.6% 7.00 0.60 12.10
    4/1/1996 3.25 -9.7% 2.93 0.53 10.13
    4/1/1995 3.60 2.00 0.80 8.00